Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEK | Q02763 | 13/20 | 0.39 |
| ▸ | KDR | P35968 | 9/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | UBE2N | P61088 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CDK1 | P06493 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4531369 | 0.91 | TEK (0.39) | TEKKDRMEN1KMT2AKDM4E | |
| SCHEMBL12409725 | 0.90 | KDM4E (0.41) | TEKKDRMEN1KMT2AKDM4E | |
| SCHEMBL12409632 | 0.88 | TEK (0.39) | TEKKDRMEN1KMT2AKDM4E | |
| SCHEMBL4527244 | 0.88 | KDM4E (0.49) | TEKKDRMEN1KMT2AKDM4E | |
| SCHEMBL6750654 | 0.88 | KDM4E (0.49) | TEKKDRMEN1KMT2AKDM4E | |
| SCHEMBL6750681 | 0.88 | KDM4E (0.49) | TEKKDRMEN1KMT2AKDM4E | |
| SCHEMBL12409608 | 0.84 | MEN1 (0.36) | TEKKDRMEN1KMT2AKDM4E | |
| SCHEMBL2181263 | 0.84 | MEN1 (0.36) | TEKKDRMEN1KMT2AKDM4E | |
| SCHEMBL12409633 | 0.83 | MEN1 (0.37) | TEKKDRMEN1KMT2AKDM4E | |
| SCHEMBL12409635 | 0.82 | MEN1 (0.36) | TEKKDRMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166163-A1 | SUBSTITUTED FUROPYRIMIDINES AND USE THEREOF | DPYD, TPMT, TYMP | TEK 374/4885KDR 1007/4885MEN1 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.